Familial Amyloidosis
📧 Sign up to get email alerts when something new happens for Familial Amyloidosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-07EMA Authorised: Onpattro (patisiran sodium) — Alnylam Netherlands B.V.
EMA has authorized Onpattro (patisiran sodium) for familial amyloidosis, with orphan designation and accelerated assessment.
-
EMA approval · 2025-03-25EMA Authorised: Onpattro (patisiran sodium) — Alnylam Netherlands B.V.
The European Medicines Agency authorised Onpattro (patisiran) for familial hereditary transthyretin-mediated amyloidosis with orphan designa…